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Factor-P Binding Protein That Can Interfere 
With Transforming Growth 
Factor-p Receptor Binding
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1 Department o f Cell Bio fogy, University o f Nijmegen, ED Nijmegen, The Netherlands
1 Ludwig Institute for Cancer Research, Biomedical Center; Uppsala, Sweden
We have characterized a 60-kDa transforming growth factor-P (TGF-p) binding 
protein that was originally identified on LNCaP adenocarcinoma prostate cells 
by affinity cross-linking of cell surface proteins by using l2Sl-TGF-p1. Binding of 
,25i-TGF-p1 to the 60-kDa protein was competed by an excess o f unlabeled TGF- 
pl but not by TGF~p2, TGF~(33, activin, or osteogenic protein-1 (OP-1), also 
termed bone morphogenetic protein-7 (BMP-7). In addition/ no binding of 125l- 
TGF-p2 and ;25l-TGF-p3 to the 60-kDa binding protein on LNCaP ceils could be 
demonstrated by using affinity labeling techniques. The 60-kDa TGF-p binding 
protein showed no immunoreactivity with antibodies against the known type I 
and type II receptors for members of the TGF-P superfamily. Treatment of LNCaP 
cells with 0.25 M NaCI, 1 ¡ixg/ml heparin/ or 10 % glycerol caused a release of 
the 60-kDa protein from the cell surface. In addition/ we found that the previously 
described TGF-P type IV receptor on GH3 cells, which does not form a hetero- 
meric complex with TGF-p receptors, could be released from the cell surface by 
these same treatments. This suggests that the 60-kDa protein and the similarly 
sized TGF-p type IV receptor are related proteins. The eluted 60-kDa LNCaP 
protein was shown to interfere with the binding of TGF-p to the TGF-p receptors, 
Thus, the cell surface-associated 60-kDa TGF-P binding protein may play a role 
in regulating TGF-p binding to TGF-P receptors. J. Cell. Physiol. 173:447-459,
1997. © 1997 Wiley-Liss, Inc,
Transforming growth factor-P (TGF-p) was described 
originally as a growth stimulator for normal rat kidney 
cells in soft agar in the presence of TGF-a (Anzano et 
al., 1983). However, many other biological activities 
have been ascribed subsequently to this factor, which 
is the prototype of a large family of structurally related 
factors (for reviews, see Massagué, 1990; Roberts and 
Sporn, 1990). Although the three highly similar mam­
malian TGF-p isoforms, TGF-pi, TGF-p2, and TGF- 
p3? mainly exert overlapping biological activities, like 
inhibition of cell growth, modulation of the immune 
response, and deposition of extracellular matrix pro­
teins, some isoform-specific activities have been de­
scribed. TGF-P 1, in contrast to TGF-P3, induces scar 
formation after wounding (Shah et al., 1995). TGF-pl 
and TGF-p3 are more potent than TGF-P2 in inhibiting 
proliferation of hematopoietic progenitor cells and en­
dothelial cells (Cheifetz et ah, 1990). Other factors that 
belong to the TGF-P superfamily are activins and inhib- 
ins, bone morphogenetic proteins (BMPs), and the 
growth and differentiation factors (GDFs).
TGF-p family members mediate their biological ac­
tivities by binding to cell surface receptors. The TGF-
P type I receptor (TpR-I; 53 kDa) and type II receptor 
(TpR-II; 75 kDa) are transmembrane serine/threonine 
kinase receptors that are directly involved in signal 
transduction (for reviews, see ten Dijke et al., 1994b, 
1996; Wrana et al., 1994; Attisano et al., 1996). After 
binding of TGF-P 1 to TpR-II, TpR-I is recruited into 
the complex and becomes phosphorylated by TpR-II on 
serine and threonine residues in the GS-box. TpR-I is 
directly responsible for downstream signal transduc­
tion that leads to a phosphorylation and heteromeriza- 
tion of particular Smads, which are shuttled subse­
quently to the nucleus where, in complex with other 
proteins, they affect the transcription of specific genes 
(for review, see Massague, 1996).
Betaglycan (200-400 kDa), also referred to as TGF- 
P type III receptor (TpR-III; Lopez-Casillas et al., 1991; 
Wang et al., 1991), and endoglin (180 kDa; Cheifetz 
et al., 1988) are structurally related transmembrane
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Fig. 1. Identification of transforming growth factor-P (TGF-p) bind­
ing proteins on LNCaP prostate adenocarcinoma cells. LNCaP cells 
(10 X 10°) were affinity labeled with 200 pM m I-TGF-pl followed by 
cross-linking with 0.28 mM disuccinimidyl suberate (DSS). Cell ly­
sates were analyzed by sodium dodecyl sulfate (SDS)-gel electrophore­
sis under reducing (R) and nonreducing (NR) conditions, followed by 
autoradiography or Fuji-X Bioimager analysis.
proteins with very short intracellular tails. They proba­
bly function in presenting TGF-P to TpK-II rather than 
in a direct participation in signal transduction. 
Whereas TpR-III binds all three TGF-P isoforms with 
equal affinity, endoglin binds TGF-P2 only weakly, 
which may explain differences in biological potencies 
of the three TGF-p isoforms in endothelial cell growth 
inhibition. In rat pituitary GH3 cells, binding of TGF- 
P to complexes of 70—74 kDa have been detected and 
referred to as the TGF-p type IV receptor (TpR-IV; 
Cheifetz et al., 1988; Yamashita et al., 1995). A TpR- 
V (400 kDa) receptor has been purified from bovine 
liver (O’Grady et al., 1991).
In addition, there are many other cell surface or ex­
tracellular matrix-associated binding proteins for TGF- 
3 that might influence signal transduction indirectly 
3y presenting ligand to the signaling receptors or by 
inhibiting receptor binding. TGF-P isoform-specific 
binding proteins have been identified as well (MacKay 
et al., 1990; MacKay and Danielpour, 1991). Several 
glycosyl-phosphatidy 1-inositol (GPI)-anchored cell sur­
face proteins have been described that bind TGF-ps in 
an isoform-specific manner (Cheifetz and Massague, 
1991; Dumont et al., 1995). Butzow et al. (1993) re­
ported the characterization of a 60-kDa TGF-p binding 
protein that associates with heparan sulfate proteogly­
cans on the cell surface of HepG2 cells and that can be 
released by 10 |ig/ml heparin or 0.25 M NaCI. Human 
a2-HS glycoprotein and its bovine counterpart, fetuin, 
a major component of fetal serum, have also been 
shown to bind several members of the TGF-P superfam­
ily (Demetriou et al., 1996). Other soluble proteins that
bind TGF-p are a2-macroglobulin (O’Connor-McCourt 
and Wakefield, 1987), collagen type IV (Paralkar et al., 
1991), fibronectin (Fava and McClure, 1987), decorin 
and biglycan (Yamaguchi et al., 1990), and thrombos- 
pondin (Murphy-Ullrich et al., 1992).
Loss of TGF-p signaling, either by absence of the 
signaling receptors or by lack of downstream signaling 
components, has been implicated in several types of
cancer (Filmus and Kerbel, 1993; Schutte et al., 1996).
The androgen-dependent prostate adenocarcinoma cell 
line LNCaP lacks expression of TpR-I due to a genetic 
alteration in the gene for this receptor (Kim et al., 
1996a). Under normal in vitro culture conditions, 
LNCaP cells are insensitive to TGF-P (Wilding et al., 
1989). The growth of the cells can be stimulated or 
inhibited by androgens like dihydrotestosterone (DHT; 
Schuurmans et al., 1988; Sonnenschein et al., 1989; 
Lee et al., 1995). Conflicting reports have been pub­
lished about the responsiveness of LNCaP cells to TGF- 
P in the presence of proliferation-modulating factors 
like DHT (Carruba et al., 1994; Kim et al., 1996b,c), 
epidermal growth factor (EGF) and TGF-a (Schuur­
mans et al., 1991; Janssen et al., 1995), or retinoic acid 
(Fong et al., 1993).
In a search for novel receptors for TGF-P, we per­
formed affinity cross-linking of cell surface proteins on 
different cell types. A 60-kDa TGF-p binding protein 
distinct from the known serine/threonine kinase recep­
tors was identified on LNCaP cells. When it was associ­
ated to the extracellular matrix of LNCaP cells, this 
60-kDa protein bound only the TGF-pl isoform. In addi­
tion, the protein interfered with binding of TGF-p to 
TGF-P receptors on mink lung epithelial MvlLu cells. 
Our data suggest that the presently characterized 60- 
kDa protein may regulate TGF-P binding to its signal­
ing receptors.
MATERIALS AND METHODS 
Cell culture
LNCaP and PC3 human prostate cancer cells, GH3 
rat pituitary tumor cells, and MvlLu cells (CCL64) 
were obtained from the American Type Culture Collec­
tion (Rockville, MD). LNCaP cells were routinely cul­
tured in RPMI 1640 medium supplemented with 10% 
fetal bovine serum, 100 units/ml penicillin, and 50 Jig/ 
ml streptomycin. PC3 cells and MvlLu cells were cul­
tured in Dulbecco’s modified Eagle’s medium (DMEM) 
containing 10% fetal bovine serum, 100 units/ml peni­
cillin, and 50 (ig/ml streptomycin. GH3 cells were grown 
in DMEM supplemented with 10% horse serum, 5% 
fetal bovine serum, 100 units/ml penicillin, and 50 fig/ 
ml streptomycin. The cells were grown in 5% C02 atmo­
sphere at 37°C.
Antibodies
Antisera against activin receptor-like kinase (ALK)- 
1, activin receptor (ActR) type I, ActR-IB, BMP receptor 
(BMPR) type IA, BMPR-IB, TpR-I, TpR-II, and endo­
glin were raised against synthetic peptides correspond­
ing to the intracellular juxtamembrane parts of the 
type I receptors, the C-terminal tail of TpR-II, and the 
intracellular part of endoglin, as described previously 
(Franzen et al., 1993b; ten Dijke et al., 1994b; Yama­
shita et al., 1994). A monoclonal antibody against TpR-
II extracellular domain was obtained from H. Ohashi
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Fig. 2. Analysis of ligand binding specificity of the 60-kDa TGF-p 
binding protein on LNCaP cells. A: Cross-linking of cell surface pro­
teins on LNCaP cells with different TGF-p isoforms. LNCaP cells (10 
x 10G) were incubated with 200 pM iacI-TGF-pl, iarT-TGF-p2, or l2r,I- 
TGF-P3, followed by cross-linking with 0.28 mM DSS. Cell lysates 
were analyzed by SDS-gel electrophoresis followed by Fuji-X Bio-
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Imager analysis. B: Competition of 12rT-TGF-pl binding to LNCaP cell 
surface proteins by excess cold TGF-p. LNCaP cells (10 X 10G) were 
incubated with 100 pM 12BI-TGF-pl in the absence or presence of 400- 
fold excess cold TGF-p 1, TGF-f}2 , or TGF-p3. After cross-linking with 
0,28 mM DSS, cell lysates were analyzed by SDS-gel electrophoresis 
followed by autoradiography.
at Ear in Brewery Company (Tokyo, Japan). Anti serum 
to the intracellular part of TpR-III was prepared 
against the synthetic peptide GETARRQQVPTSPPA- 
SENSS and was obtained from K. Miyazono (Cancer 
Institute, Tokyo, Japan), Antiserum against the GS- 
domain of T(3R-I was prepared against the synthetic 
peptide DLIYDMTTSGSGSG. The peptides were syn­
thesized with an Applied Biosystems (Foster City, CA) 
430A peptide synthesizer by using t-butoxycarbonyl 
chemistry and were purified by reverse-phase high-per- 
formance liquid chromatography. The peptides were 
coupled to keyhole limpet hemocyanin (Calbiochem- 
Behring, San Diego, CA) by using glu tar aldehyde, 
mixed with Freund's adjuvant, and used to immunize 
rabbits. Antisera against ActR-II and BMPR-II were 
raised against synthetic peptides, as described pre­
viously (Ichijo et al., 1993; Rosenzweig et al., 1995). 
Antiserum against bovine fetuin was obtained from 
K.M. Dziegielewska, and antisera against a2HS-glyco-
protein were obtained from K.M. Dziegielewska and W, 
J ahnen-D e ch ent.
Affinity cross-linking studies and 
im m unoprécipitations
Human recombinant TGF-p 1 was obtained from H. 
Ohashi at Kirin Brewery Company, TGF-P2 was ob­
tained from B. Pratt at Genzyme Corporation (Fra­
mingham, MA), and TGF-P3 was obtained from N. Cer- 
letti at CIBA-GEIGY A.G. (Basel, Switzerland), Activin 
A was obtained from Y. Eto at Ajinomoto Company 
(Kawasaki, Japan), and osteogenic protein-1 (OP-1), 
BMP-2, and murine growth and differentiation factor 
(GDF)-5 were obtained from T.K, Sampath at Creative 
Biomolecules, Inc. (Hopkinton, MA). The ligands were 
iodinated according to the chi or amine-T method (Frolik 
et al., 1984). Cells were incubated for 3 hr on ice in 
binding buffer [phosphate-buffered saline (PBS) con­
taining 0.9 mM CaCl2, 0,49 mM MgCl2, and 0,1% bo-
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vine serum albumin] in the presence of 200 pM ofiodin- 
ated ligand. For competition binding assays, 400-fold 
excess of unlabeled ligand was added. After labeling of 
the cells, they were washed three times in binding 
buffer followed by one wash with binding buffer free 
of bovine serum albumin. Cross-linking with 0.28 mM 
disuccinimidyl suberate (DSS) was done in the same 
buffer for 15 min on ice. The cross-linking was 
quenched with detachment buffer containing 10 mM 
Tris-HCl, pH 7,5, 1 mM EDTA, 10% glycerol, and 0.3 
mM phenylmethylsulfonyl fluoride (PMSF) or with 
PBS buffer containing 10 mM Tris-HCl, pH 7.5, and 
0.3 mM PMSF. The cells were scraped off the plates in 
detachment buffer, and they were lysed after centrifu­
gation in solubilization buffer (125 mM NaCl, 10 mM 
Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM PMSF, 1.5%
trasylol, and 1% Triton X-100) for 40 min on ice. In case 
of subsequent immunoprécipitations with anti-TGF-p 
receptor antibodies, the immunocomplexes were col­
lected on protein-A sepharose beads (Immunosorb; EC 
Diagnostics AB, Uppsala, Sweden). The beads were 
centrifuged and washed three times with solubilization 
buffer followed by one wash in distilled water. Immuno- 
complexes and solubilized cell extracts were mixed with 
sodium dodecyl sulfate (SDS) sample buffer (80 mM 
Tris-HCl, pH 8.8, 0.01% bromphenol blue, 24% glycerol, 
4% SDS, and 10 mM dithiothreitol), boiled for 3 min, 
and separated by SDS-gel electrophoresis using a 5,0- 
12.5% gradient polyacrylamide gel. For autoradio­
graphic analysis, gels were exposed to Hyperfilm MP 
(Amersham, Buckinghamshire, United Kingdom).
D ith iothreitol treatm ent
LNCaP cells and PC3 cells were treated with or with­
out 1 mM dithiothreitol (DTT) in binding buffer without 
bovine serum albumin at 37°C for 8 min and were then 
affinity labeled with 200 pM 125I-TGF-|3 followed by 
cross-linking with 0.28 mM DSS. The cross-linked com­
plexes were analyzed by SDS-gel electrophoresis and 
were visualized by using a Fuji-X Bioimager (Tokyo, 
Japan).
E ndoglycosidase F treatm ent
LNCaP cells and PC3 cells were incubated with 200 
pM 125I-TGF-P and cross-linked with 0.28 mM DSS. 
Cross-linked complexes were incubated with 0.5 unit 
of endoglycosidase F (Boehringer Mannheim Biochemi­
cals, Indianapolis, IN) in a buffer containing 100 mM 
sodium phosphate, pH 6.1, 50 mM EDTA, 1% Triton 
X-100, 0.1% SDS, and 1% 2-mercapto ethanol at 37°C 
for 24 hr. Samples were boiled in SDS sample buffer, 
analyzed by SDS-gel electrophoresis, and visualized by 
using a Fuji-X Bio Imager.
N orthern blot analysis
Isolation of total RNA and Northern blotting were 
performed as described previously (Franzén et al., 
1993a). The filters were hybridized and washed with a 
TpR-I-specific cDNA probe, also as described previously 
(Franzén et al., 1993b).
*  ►
M itogenic assays
For growth inhibition assays, LNCaP cells were 
seeded in RPMI1640 medium containing 10% fetal bo­
vine serum and antibiotics at a density of 5.0 X 104
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Fig. 3, Biochemical characterization of TGF-P cross-linked protein 
complexes on LNCaP cells. A: Immunoprécipitation of m I-TGF-pi 
cross-linked protein complexes from LNCaP cells with TGF-P receptor 
antisera. LNCaP cells (40 x 106) were affinity labeled with 200 pM 
12fiI-TGF-pl followed by cross-linking with 0.28 mM DSS, Aliquots of 
cell lysates were analyzed directly by SDS-gel electrophoresis followed 
by Fuji-X Biolmager analysis or were first subjected to immunoprécip­
itation (IP) by using antisera against TGF-p type I (TpR-I), TpR-II, 
TpR-III, and endoglin. B: Endoglycosidase F treatment of 12fiI-TGF- 
pi affinity cross-linked protein complexes on LNCaP ceils and PC3 
cells, LNCaP cells (10 X 10G) and PC3 cells were affinity labeled with 
200 pM 12rT-TGF-pl followed by DSS (0.28 mM) cross-linking. Cell 
lysates were treated with 0.5 unit of endoglycosidase F (Endo F) for 
24 hr at 37°C and analyzed by SDS-gel electrophoresis followed by 
Fuji-X Biolmager analysis. C: Dithiothreitol (DTT) treatment of 
LNCaP cells and PC3 cells followed by 12rT-TGF«pi affinity cross- 
linking. LNCaP cells (10 X 10r>) and PC3 cells were incubated with 
or without 1 mM DTT in binding buffer without bovine serum albumin 
for 8 min at 37°C. Cells were subsequently incubated with 200 pM 
125I-TGF-pi followed by cross-linking with 0.28 mM DSS, Cell lysates 
were analyzed by SDS-gel electrophoresis followed by Fuji-X Biol­
mager analysis, D: Northern blot analysis of TpR-I expression in 
LNCaP cells. Total RNA (10 jag) from human embryonic lung cells 
(HEL), PC-3 cells, a previously described PC-3 subline PC-3U (Fran­
zén et al., 1993a), LNCaP cells, human lung carcinoma cells (A549). 
and human breast adenocarcinoma cells (MCF-7) was subjected tc 
Northern blot analysis by using a TpR-I specific probe. E: Immunopré­
cipitation of 12RI-TGF-pi cross-linked protein complexes from LNCal 
cells with antisera against type I and type II receptors for m em b en  
of the TGF-P superfamily. LNCaP cells (70 X 10°) were affinity labelet 
with 200 pM 125I-TGF-pl followed by cross-linking with 0.28 mM DSS 
Aliquots of cell lysates were analyzed directly by SDS-gel electropho 
resis followed by autoradiography or were first subjected to immuno 
precipitation (IP) by using antisera against activin receptor-like ki 
nase 1 (ALK-1), activin receptor I (ActR-I), bone morphogenetic pro 
tein receptor (BMPR)-IA, ActR-IB, TpR-I, BMPR-IB, and TpR-II.
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cells per well in 24-well tissue culture plates. The next 
day, growth factors were added at various concentra­
tions. After treatment for 20 hr, cells were incubated 
with 0.1 ¡LiCi/ml [nH]thymidine (Amersham) for an addi­
tional 2 hr. Cells were fixed in ice-cold 5% trichloroace­
tic acid for 20 min, washed with water, and solubilized 
in 200 jil 0.1 M NaOH at room temperature. [3H]thymi- 
dine incorporation was measured in a liquid-scintilla- 
tion (3 counter by using Ecoscint (National Diagnostics, 
Manville, NJ).
The effect of TGF-P on DHT-mediated cellular prolif­
eration of LNCaP cells was measured by [3H]thymidine 
incorporation assays. Cells were seeded at a density of 
2.5 X 104 cells per well in 24-well tissue culture plates 
in phenol red-free RPMI 1640 medium containing 10% 
charcoal stripped fetal bovine serum and antibiotics. 
After 2 days, culture medium was refreshed, and cells 
were stimulated with various concentrations of DHT 
in the presence or absence of 400 pM TGF-pl. After 2 
days, [ H] thymidine was added for 2 hr, and [3H]thymi­
dine incorporation was measured, as described above.
Extraction of the 60-kDa TGF-P binding protein
from the cell surface
LNCaP cells and GH3 cells that were grown to conflu- 
ency in 25-'em2 flasks were affinity labeled with 200 pM 
125I-TGF-pi followed by DSS cross-linking. Extraction of 
TGF-p binding proteins from the cell surface was per­
formed by incubations twice for 15 min on ice in PBS 
buffer containing different concentrations of NaCl, hepa­
rin, or glycerol. Cells were solubilized and prepared for 
SDS-gel electrophoresis, as described above. The two 
washes were pooled, and proteins were precipitated in 
10% trichloroacetic acid for 30 min on ice followed by 15 
min centrifugation and an acetone wash. The samples 
were boiled in sample buffer and separated by SDS-gel 
electrophoresis followed by autoradiography.
Com petition binding assay w ith the 60-kDa
TGF-p binding protein
Confluent LNCaP cells (25 X 106 cells) in 175-cm2 
flasks were washed twice in binding buffer in the ab­
sence of bovine serum albumin. Cells were scraped off 
the flasks in 10 ml of bovine serum albumin-free bind­
ing buffer, spun down for 5 min at 4°C, and resus­
pended in 1 ml of PBS containing 10% glycerol. Extrac­
tion of the 60-kDa TGF-P binding protein was done for 
30 min at 4°C. Thereafter, cells were spun down, and 
the supernatant was centrifuged at 13,000 rpm for 30 
min at 4°C. An affinity cross-linking assay was per­
formed on 2.5 X 106 MvlLu cells in six-well culture 
plate dishes using 20 pM 125I-TGF~P in 1 ml of PBS 
containing 10% glycerol and 0.1% bovine serum albu­
min in the presence or absence of 60-kDa TGF-p bind­
ing protein eluted from 25 X 106 LNCaP cells. Samples 
were analyzed by SDS-gel electrophoresis and autora­
diography.
RESULTS
Identification of a 60-kDa TGF-pi cell surface
binding protein  in LNCaP cells 
distinct from TGF-p receptors
Binding of 125I-TGF-pi to LNCaP cells followed by 
cross-linking with DSS revealed complexes of approxi­
mately 70—74 kDa (Fier. 1). Subtracting the m o le c u la r
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Fig. 4. Analysis of responsiveness of LNCaP cells to members of the 
TGF-p superfamily and identification of ligand binding to receptors. 
A: Cellular proliferation of LNCaP cells in the presence of different 
members of the TGF-p superfamily. LNCaP cells were seeded at a 
density of 50,000 cells/well in 24-well plates and were stimulated for 
20 hr with 800 pM activin A, 6.25 nM BMP-2 , 6.25 nM growth and 
differentiation factor 5 (GDF-5), 6.25 nM osteogenic protein-1 COP-1 ), 
and 800 pM TGF'pl. Inhibition of cellular proliferation was measured
by [H]-thymidine incorporation, and results are expressed in percent­
age of unstimulated control. Each column represents the mean of 
triplicate observations. The vertical bars denote standard deviations. 
B: Cellular proliferation of LNCaP cells in the presence of different 
concentrations of dihydrotestosterone (DHT) and/or TGF-pi. LNCaP 
cells were seeded at a density of 25,000 cells/well in 24-well plates. 
Cells were grown in the presence of different concentrations of DHT 
and/or 400 pM TGF-pl for 4 days. [:>Ii]-thymidine incorporation was 
measured, and results are expressed in percentage of unstimulated 
control, Each column represents the mean of triplicate observations. 
The vertical bars denote standard deviations. C: Analysis of activin 
receptor expression in LNCaP cells. LNCaP cells (30 X 10fi) were 
incubated with 400 pM 125I-activin A followed by cross-linking with 
0.28 mM DSS. Aliquots of cell lysates were analyzed directly by SDS- 
gel electrophoresis followed by autoradiography or were first subjected 
to immunoprécipitation (IP) by using antisera against activin recep­
tors. D: Analysis of OP-1 receptor expression in LNCaP cells. LNCaP 
cells (60 X 10e) were incubated with 250 pM m l-OV-l followed b> 
cross-linking with 0.28 mM DSS. Aliquots of cell lysates were analyzed 
directly by SDS-gel electrophoresis followed by Fuji-X Bioimager anal­
ysis or were first subjected to immunoprécipitation (IP) by using anti­
sera against OP-1 receptors followed by autoradiography.
mass of the cross-linked monomeric TGF-P 1 results ir 
the estimated size of approximately 60 kDa. Undei 
nonreducing conditions, only one TGF-P 1 cross-linkec 
complex of 67 kDa was observed (Fig. 1). Cross-linking
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Fig. 4. (Continued.)
studies using 125I-TGF-(î2 and 12BI-TGF-p3 gave weaker 
bands, suggesting that the affinity of the 60-kDa pro­
tein for these TGF-p isoforms is much lower than the 
affinity for TGF-pl (Fig. 2A). The binding of 12GI-TGF- 
pi to the 60-kDa protein as well as to the T(3R-III (for 
its identification, see Fig. 3A) was fully competed with 
400-fold excess of unlabeled TGF-|31 (Fig. 2B), indicat­
ing specificity in binding. Compared with TGF-pl, a 
400 fold-excess of TGF-p2 or TGF-P3 competed to a 
lesser extent with 12BI-TGF~pl for binding to the 60-kDa 
protein, whereas the binding of 125I-TGF-|31 to TpR-III 
was clearly displaced. Activin and OP-1 also failed to 
compete for binding of 125I-TGF-pl to the TGF-p bind­
ing proteins on LNCaP cells (data not shown). These 
results indicate that the 60-kDa protein on LNCaP cells 
displays TGF-pi isoform-specific binding.
Immunoprécipitations with antisera raised against 
the intracellular domain of TpR-I, TpR-II, TBR-III, and 
endoglin failed to bring down the 60-kDa ^I-TGF-pl 
cross-linked protein complexes (Fig. 3A). TpR-III ap­
peared to be expressed by LNCaP cells, because its 
presence was confirmed by immunoprécipitation of the
I-TGF-pi cross-linked, 200-kDa protein complexes 
using the TpR-III antiserum. To further explore the 
possibility that the 60-kDa TGF-P binding protein on 
LNCaP cells is related to the similarly sized TpR-I, the 
following experiments were performed. TpR-I is known 
to contain N-linked glycosylation, which can be re­
moved by treatment with endoglycosidase F, However, 
endoglycosidase F treatment of LNCaP cells did not alter 
the size of the TGF-pl binding complexes (Fig. 3B), indi­
cating that the proteins do not contain N-linked carbohy­
drate chains. Binding of TGF-P to TpR-I can be abolished 
by DTT. However, when LNCaP cells were treated with 
DTT preceding affinity cross-linking studies, the 70-74 
kDa protein complexes could still be detected (Fig. 3C).
In PC-3 cells, TpR~I was clearly affected by endoglycosi­
dase F or DTT treatment. In addition, these experiments 
revealed that PC-3 cells also contain the 70-74 kDa pro­
tein complexes. Moreover, Northern blot analysis re­
vealed that LNCaP cells lack expression of TpR-I in con­
trast to other cell lines examined (Fig. 3D). Taken to­
other, these observations indicate that the 60-kDa 
LNCaP protein is distinct from TpR-I.
To examine whether the TGF-p binding components 
are related to other known serine/threonine kinase type
I receptors, we subjected the 125I-TGF-P1 affinity-la­
beled, cross-linked complexes from LNCaP cells to im­
munoprécipitation with specific antisera raised against 
the known type I receptors [activin receptor-like ki­
nases (ALK) 1—6; ten Dijke et al., 1994a] and with an 
antibody raised against the GS domain. These antisera 
as well as antisera against the extracellular domain of 
TpR-II did not immunoprecipitate any of the TGF-pl 
protein complexes in LNCaP cells (Fig. 3E and data 
not shown).
LNCaP cells are TGF-p resistant but respond  
to other TGF-P superfam ily members
The growth-modulating effects of different members 
of the TGF-p superfamily on LNCaP cells were tested 
by [3H]-thymidine incorporation assays. TGF-pl had 
no significant antimitogenic effect on LNCaP cells, 
whereas activin and GDF-5 clearly inhibited the 
growth of LNCaP cells to less than 50% of control cells 
(Fig. 4A). The inhibition was even more pronounced 
with the addition of BMP-2 or OP-1 (Fig. 4A). Kim et al. 
(1996c) have reported the abolition of DHT-mediated 
cellular proliferation by TGF-p. Therefore, the potential 
effect of TGF~P on DHT-stimulated LNCaP cells was in­
vestigated (Fig. 4B). Although stimulation of LNCaP cells 
with increasing concentrations of DHT resulted in a typi-
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Fig. 5. Determination of the elution characteristics of the 60-kDa 
TGF-fJ binding protein. LNCaP cells were grown to confluency in 25- 
cm2 flasks. Cell surface proteins on LNCaP cells were affinity cross- 
linked with 200 pM 12BI-TGF-p 1 followed by two washes with different
concentrations of NaCl (A) and heparin (B) or glycerol in combination 
with heparin (CX The two washes from each flask were pooled and 
trichloroacetic acid precipitated. Cells were lysed, and all samples were 
analyzed by SDS-gel electrophoresis followed by autoradiography.
cal bell-shaped growth curve (Schuurmans et al., 1988; 
Sonnenschein et al., 1989; Lee et al., 1995), showingmax- 
imum stimulation of cell growth at 10"10 M DHT? the 
addition of TGF~pi did not affect this DHT-induced prolif­
eration. Thus, although LNCaP cells do have the potency 
to react on several members of the TGF-P superfamily, 
they are nonresponsive to TGF-P itself.
Cross-linking studies with radiolabeled ligands 
showed that* in LNCaP cells, activin A bound to ActR- 
IB and ActR-II (Fig. 4C), whereas OP-1 bound to 
BMPR-I and BMPR-II and weakly to ActR-II (Fig. 4D). 
Apparently, activin A and OP-1 did not bind to the 60- 
kDa TGF~P binding protein.
TGF-p 60-kDa binding protein is a cell 
surface-associated protein
To explore the basis for the cell membrane association 
of the 60-kDa TGF-P binding protein, we investigated 
whether the 125I-TGF-pl cross-linked protein complexes 
could be released by treatment of the cell cultures with 
NaCl (Fig. 5A). Elution of the protein complexes from the 
cell surface into the medium could be detected clearly 
after incubation in buffers containing 0.25 M or more of 
NaCl. Incubation of LNCaP cells in 1 jig/ml or more of 
heparin in PBS after affinity cross-linking also resulted 
in a release of the TGF-p-bound complexes (Fig. 5B). Hep­
arin is known to dissociate proteins that are attached to
glycosaminoglycans. In addition, release of the TGF-p- 
bound protein complexes could be achieved after incuba­
tion in 10% glycerol in PBS (Fig. 5C).
TGF-P 58-62 kDa binding proteins on GH3 cells 
have properties similar to the 60-kDa TGF-pi 
binding protein from LNCaP cells
GH3 cells contain TGF-P binding proteins similar in 
size to the 60-kDa protein on LNCaP cells and that 
have been designated TGF-P type IV receptors. There­
fore, we investigated whether the TGF-P binding pro­
tein on GH3 cells showed the same isoform specificity 
and cell surface-associated characteristics as the 
LNCaP TGF-P binding protein. Regarding the isoform 
specificity of the proteins on GH3 cells, the 69-kDa. 
cross-linked TGF-P type I receptor, which had high af­
finity for all three TGF-p isoforms, partly overlapped 
with the complex containing the 60-kDa componeni 
(Fig. 6A), making firm conclusions difficult. The uppei 
protein band in the 70-74 kDa region appeared to b( 
somewhat weaker when 125I-TGF~p2 or 12GI-TGF-p£ 
were used in the cross-linking studies, which is in lin( 
with our observations for the 60-kDa TGF-P binding 
protein from LNCaP cells. Similar to our findings fo: 
the TGF-pi binding component in LNCaP cells, the 70- 
74 kDa complexes on GH3 cells were released upoj 
treatment with 0.5 M NaCl, 10 jig/ml heparin (Fig. 6B!
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Fig. 6. Characterization of the TGF-p binding proteins on GH3 cells, 
A: Identification of TGF-p binding characteristics ofTpR-IV on GH3 
cells. GH3 cells (10 X 10fi) were incubated with 200 pM 12CI-TGF- 
pi, iyr,I-TGF-p2 , or IaBI-TGF-p3 and cross-linked with 0.28 mM DSS. 
Aliquots of cell lysates were analyzed directly by SDS-gel electropho­
resis followed by Fuji-X Bioimager analysis or were first subjected to 
immunoprécipitation (IP) by using an antiserum against TpR-I, Bî 
Sodium chloride- and heparin-dependent release of TGF-p cross- 
linked protein complexes on GH3 cells. GH3 cells were grown to con- 
fluency in 25-cm2 flasks and incubated with r25I-TGF-pl followed by 
cross-linking with 0.28 mM DSS. Cells were washed twice with phos­
phate-buffered saline (PBS; C), 0.5 M NaCl in PBS (N), or 10 ng/ml 
heparin in PBS (H). The two washes were pooled and trichloroacetic 
acid precipitated. Cells were lysed, and all samples were analyzed by 
SDS-gel electrophoresis followed by autoradiography.
or 10% glycerol (data not shown), whereas TpR-I was 
not eluted from the cells under these conditions.
TGF-P 60-kDa protein interferes with TGF-p
receptor binding
The 60-kDa protein extracted from LNCaP cells by 
a wash with 10% glycerol in PBS was tested for its 
effect on 12rT-TGF-p binding to the TGF-p receptors on
MvlLu cells (Fig. 7), MvlLu cells do not contain the 
60-kDa TGF-p binding protein, yet they express high 
levels of TpR-I, TpR-II, andTpR-III. Therefore, it seems 
to be a suitable model system to investigate the possible 
function of the 60-kDa TGF-p binding protein from 
LNCaP cells. In the presence of 60-kDa LNCaP-derived 
protein, the binding of all three TGF-P isoforms to the 
TGF-p receptors was inhibited. After incubation of 125I- 
TGF-pl with the glycerol extract followed by cross-link­
ing, only the 70-74 kDa protein complexes were de­
tected (data not shown), indicating that the decrease 
in TGF-p binding to its receptors was mediated by the 
60-kDa protein and not by other proteins present in 
the wash. These results suggest that, in a soluble form, 
the 60-kDa protein has affinity for all three TGF-P iso­
forms. Thus, the 60-kDa TGF-P binding protein can 
modulate the binding of TGF-J3 to its receptors, im­
plying that it might regulate TGF-p receptor-mediated 
signaling.
DISCUSSION
This study describes the characterization of a 60-kDa 
TGF-p binding protein that was originally identified 
on LNCaP cells by affinity cross-linking of cell surface 
proteins with 125I-TGF-pl. Our results show that the 
60-kDa TGF-P binding protein is distinct from TPR-I, 
TpR-II, and other known type I receptors for members 
of the TGF-p superfamily. Rather than being a trans- 
membrane protein, the 60-kDa TGF-p binding protein 
is associated to the cell surface of LNCaP cells. It ap­
pears to be present on multiple cell types, including 
PC-3 cells and GH3 cells, and can regulate the access 
of TGF-P to its receptors.
The cell surface-associated TGF-P binding protein on 
LNCaP cells exists in multiple forms, observed as 70- 
74 kDa, TGF-P bound protein complexes upon analysis 
by SDS-gel electrophoresis (Fig. 1). Because the 70- 
74 kDa protein complexes include 12-kDa subunits of 
monomeric cross-linked TGF-P, the actual size of the 
binding protein is estimated to approximately 60 kDa. 
Under nonreducing conditions, the multiple TGF-P 
bound protein complexes run slightly faster, as a 67- 
kDa component (Fig. 1), suggesting that the 60-kDa 
TGF-p binding protein contains cysteine bridges.
Although LNCaP cells do express TpR-III (Fig. 3A), 
they lack expression of TPR-I (Fig. 3A—E) due to a 
genetic alteration in the gene encoding this receptor 
(Kim et al., 1996a), and the expression level of TpR-II 
is very low (Earn et al., 1996c). Transfection of TpR-I 
into LNCaP cells results in recovery of TGF-p respon­
siveness, showing that the TGF-p signaling pathway 
downstream of TpR-I is intact in LNCaP cells (Kim et 
al., 1996a). There are contradictory reports, however, 
on the responsiveness of LNCaP cells to TGF-P in the 
presence of proliferation-inducing factors, like dihydro- 
testosterone (Schuurmans et al., 1988; Wilding et al., 
1989; Kim et al., 1996b,c). Although TGF-p has been 
described to suppress the mitogenic activity of 10~10 M 
DHT in LNCaP cells (Kim et al., 1996c), we observed 
no inhibition of the growth-stimulatory effect of 10-10 
M DHT on LNCaP cells by the addition of TGF-p. Cross- 
linking studies on 1 0 M DHT-stimulated LNCaP 
cells did not indicate an up-regulation of expression of 
TGF-P receptors or TGF-P binding proteins compared 
with untreated cells (data not shown). Apparently, the
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Fig. 7. Functional characterization of the 60-kDa TGF-p binding pro­
tein. Affinity cross-linking of 125I-TGF~p to TGF-p receptors on mink 
lung epithelial cells (MvlLu) in the presence of LNCaP-eluted 60- 
kDa TGF-p binding protein, The 60-kDa TGF-p binding proteins were 
elated from LNCaP cells with 10 % glycerol in PBS. MvlLu cells (2.5 
X 1 0 c) were incubated with 20 pM ^I-TQF-pi, 125I-TGF-P2, or W0I-
TGF-P3 in binding buffer without glycerol or LNCaP-eluted proteins, 
or in binding buffer with 10% glycerol but in the absence of LNCaP- 
eluted proteins, or in binding buffer containing 10% glycerol and cell 
surface-eluted proteins from 25 X 1G6 LNCaP cells, followed by cross- 
linking with 0.28 mM DSS. Cell lysates were analyzed directly by 
SDS-gel electrophoresis followed by autoradiography.
60-kDa TGF-p binding protein on LNCaP cells is not 
able to directly transduce growth-modulating TGF-p
EL c t i v i t i  6  S
The 60-kDa protein identified on LNCaP cells ap­
peared to bind TGF-pl with higher affinity than TGF- 
p2 and TGF-|33. The affinity constant of the 60-kDa 
protein for TGF-pi remains to be determined. Activin 
A and OP-1 did not bind to the 60-kDa protein. Isoform- 
specific TGF-p binding proteins have been described 
that are attached to the cell membrane via a GPI an­
chor (Cheifetz and Massague, 1991; Dumont et al., 
1995). The 60-kDa TGF-p binding protein from LNCaP 
cells is not GPI anchored, because its release could not 
be induced by phosphatidyl-inositol-phospholipase C 
(data not shown). To our knowledge, this is the first 
demonstration of a protein that binds TGF-pl and TGF-
P3 with different affinity. TGF-pl and TGF-P3 have 
very similar in vitro biological activities (Cheifetz et 
al., 1990). However, they differ in their activity with 
respect to scar formation (Shah et al,, 1995).
Dissociation of the 70-74 kDa TGF-P cross-linked 
protein complexes from LNCaP cells by sodium chloride 
or heparin indicated that the 60-kDa TGF-P binding 
protein is associated to structures at the cell surface, 
perhaps to heparan sulfate proteoglycans. Heparin can 
compete for binding of proteins that are attached to 
heparan sulfate proteoglycans. The ability of the 60- 
kDa TGF-p binding protein from LNCaP cells to be 
eluted by salt or heparin is reminiscent of the charac­
teristics of a previously described 60-kDa TGF-p bind­
ing protein localized in the extracellular matrix oi 
HepG2 cells (Biitzow et al., 1993). The affinity constant
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of the HepG2 60-kDa protein for TGF-p is 1.6 nM, 
which is comparable to the affinity of TpR-III for TGF- 
p (1.9 nM) described by Andres et al. (1989). It remains 
to be determined whether the 60-kDa TGF-p binding 
protein on HepG2 cells exerts TGF-P isoform specificity 
as well.
The identity of the 60-kDa TGF-P binding protein is 
unknown. Certain components known to bind TGF-P, 
like a2-macroglobulin, fibronectin, and decorin (Fava 
and McClure, 1987; O’Connor-McCourt and Wakefield, 
1987; Yamaguchi et al., 1990), can be excluded as candi­
dates in view of their differences in size. Recently, bo­
vine fetuin and its human counterpart, a2-HS glycopro­
tein, with molecular sizes of 60 kDa, have been de­
scribed to bind several members of the TGF-P 
superfamily (Demetriou et al., 1996). However, the 
characteristics of the 60-kDa protein from LNCaP cells 
make it unlikely that it is fetuin or a2-HS glycoprotein. 
Whereas fetuin and a2~HS glycoprotein have highest 
affinity for BMPs and bind with weaker affinity to TGF- 
(3s, the 60-kDa protein from LNCaP cells has highest 
affinity for TGF-P and no appreciable affinity for activin 
A or BMPs. Fetuin and a2-HS glycoprotein contain a 
number of N- and O-glycosylated chains (Dziegielewska 
et al., 1990). However, endoglycosidase F treatment of 
the 60-kDa protein from LNCaP cells cross-linked with 
125I"TGF-P did not result in faster migration on SDS- 
gel electrophoresis. Cross-linking of radiolabeled TGF- 
P to calf serum, in which fetuin is abundantly present 
(for review, see Brown et al., 1992), or to commercial 
a2-HS glycoprotein revealed TGF-P bound protein com­
plexes distinct from the 70-74 kDa TGF-p cross-linked 
complexes on LNCaP cells (data not shown). In addi­
tion, we were unable to immunoprecipitate cross-linked 
125I-TGF~pi complexes from LNCaP cells by using anti­
sera against a2-HS glycoprotein; moreover, these anti­
sera did not recognize the eluted 60-kDa TGF-P binding 
protein by using immunoblotting (data not shown). The 
60-kDa TGF-P binding protein identified from HepG2 
cells by Btitzow et al. (1993) was shown to be produced 
by these cells, thereby excluding serum delivery.
The 60-kDa TGF-P binding protein is possibly a fol- 
listatin-like protein. Follistatin is an activin binding 
protein that inhibits activin receptor binding. Like fol­
listatin (Ueno et al., 1987; Inouye et al., 1992; Sugino 
et al., 1993), the 60-kDa TGF-p binding protein inhibits 
signaling of TGF-P superfamily members, and it may 
associate to heparan sulfate proteoglycans on the cell 
surface.
The 70-74 kDa TGF-P binding protein complexes 
have been observed in several cell lines, like HEP-G2 
cells, HEP-G3 cells, HT-12 cells (Btitzow et al., 1993), 
and PC-3 cells (Fig. 3B,C). In rat pituitary GH3 cells, 
TGF-p binding protein complexes with sizes similar to 
the 60-kDa binding protein on LNCaP cells have been 
identified (Cheifetz et al., 1988; Yamashita et al., 1995) 
and are referred to as TGF-(3 type IV receptor. We 
showed that TpR-IV can be eluted from the cell surface 
of GH3 cells by salt, heparin, and glycerol in a manner 
similar to what we observed for the 60-kDa protein 
on LNCaP cells. In addition, Yamashita et al. (1995) 
previously showed that a treatment of GH3 cells with 
endoglycosidase F did not result in a shift in molecular 
weight of the 70-74 kDa TGF-p bound protein com­
plexes in SDS-gel electrophoresis and that transient
DTT treatment did not abolish the binding of TGF-P, 
similar to the 60-kDa protein from LNCaP cells. There­
fore, we conclude that TPR-IV is a cell-associated TGF- 
P binding protein that may be related to the 60-kDa 
protein from LNCaP cells. We are currently investigat­
ing whether the TpR-IV on GH3 cells and the 60-kDa 
TGF-p binding protein on LNCaP cells exert the same 
biological activities.
In soluble form, the 60-kDa LNCaP protein was 
shown to impede the binding of TGF-p to the TpRs, 
suggesting that it may inhibit TGF-p signaling. The 
effects of the 60-kDa component on TGF-P 1-induced 
growth inhibition could not be tested directly due to 
the presence of growth-promoting contaminants in the 
partially purified preparation of the 60-kDa compo­
nent. Although affinity cross-linking of iodinated TGF- 
p to the glycerol-eluted LNCaP extract revealed that 
the 60-kDa protein is the only TGF-P binding protein, 
the 60-kDa TGF-P binding protein is present in very 
low abundance (data not shown). Therefore, it seems 
to be inevitable that, in order to clarify the role of the 
60-kDa TGF-P binding protein on modulation of TGF- 
P action, the 60-kDa TGF-P binding protein has to be 
purified. Interestingly, soluble 60-kDa TGF-p binding 
protein, in contrast to its cell surface-associated con­
figuration, does have affinity for all three TGF-P iso­
forms. Discrepancies in TGF-p binding affinities of sol­
uble and cell surface-associated 60-kDa protein are 
subject for further studies. When it is bound to the cell 
surface, the 60-kDa TGF-p binding protein may also 
regulate binding to TpRs. The 60-kDa protein was not 
coimmunoprecipitated with TpR-I in GH3 cells (Fig. 
6A; Yamashita et al., 1995), suggesting that it may 
not be involved in ligand presentation to the receptors. 
Thus, the 60-kDa TGF-P binding protein most likely 
sequesters ligand and neutralizes TGF-p bioactivity. 
Alternatively, it may have a storage function for TGF- 
P at the cell surface and extracellular matrix from 
which it can be released in active form, e.g., during 
wound repair. Thus, the 60-kDa cell surface-associated 
TGF-P binding protein identified on LNCaP cells might 
play an important role in modulating isoform-specific 
TGF-P activities.
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